Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company ProgressBusiness Wire • 08/02/21
Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021Business Wire • 07/27/21
Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding DebtBusiness Wire • 07/19/21
Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of DirectorsBusiness Wire • 06/24/21
Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare ConferenceBusiness Wire • 05/25/21
Verastem's VS-6766/Defactinib Combo Gets Breakthrough Therapy Tag For Ovarian Cancer; BTIG Upgrades StockBenzinga • 05/24/21
Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian CancerBusiness Wire • 05/24/21
Verastem Oncology Reports First Quarter 2021 Financial Results and Highlights Recent Company ProgressBusiness Wire • 05/11/21
Verastem Oncology Reports Fourth Quarter and Full Year 2020 Financial Results, Clinical Updates and Guidance for Key Milestones in 2021 and 1H 2022Business Wire • 03/18/21
Verastem Oncology to Participate in the H.C. Wainwright Global Life Sciences ConferenceBusiness Wire • 03/02/21